NASDAQ:CORT Corcept Therapeutics (CORT) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free CORT Stock Alerts $25.30 -0.02 (-0.08%) (As of 03:30 PM ET) Add Compare Share Share Today's Range$25.19▼$25.6950-Day Range$21.10▼$25.3252-Week Range$20.87▼$34.28Volume422,458 shsAverage Volume1.60 million shsMarket Capitalization$2.62 billionP/E Ratio26.63Dividend YieldN/APrice Target$33.79 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Corcept Therapeutics alerts: Email Address Corcept Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside32.5% Upside$33.79 Price TargetShort InterestBearish22.65% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.40Based on 2 Articles This WeekInsider TradingSelling Shares$1.31 M Sold Last QuarterProj. Earnings Growth41.30%From $0.92 to $1.30 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.59 out of 5 starsMedical Sector93rd out of 939 stocksPharmaceutical Preparations Industry35th out of 433 stocks 3.3 Analyst's Opinion Consensus RatingCorcept Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.79, Corcept Therapeutics has a forecasted upside of 32.5% from its current price of $25.49.Amount of Analyst CoverageCorcept Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted22.65% of the float of Corcept Therapeutics has been sold short.Short Interest Ratio / Days to CoverCorcept Therapeutics has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.Change versus previous monthShort interest in Corcept Therapeutics has recently increased by 1.81%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCorcept Therapeutics does not currently pay a dividend.Dividend GrowthCorcept Therapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCorcept Therapeutics has received a 65.19% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Corcept Therapeutics is -0.85. Previous Next 1.3 News and Social Media Coverage News SentimentCorcept Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Corcept Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for CORT on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,308,371.00 in company stock.Percentage Held by Insiders19.80% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.61% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Corcept Therapeutics are expected to grow by 41.30% in the coming year, from $0.92 to $1.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corcept Therapeutics is 26.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.13.Price to Earnings Ratio vs. SectorThe P/E ratio of Corcept Therapeutics is 26.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 200.83.Price to Book Value per Share RatioCorcept Therapeutics has a P/B Ratio of 5.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Corcept Therapeutics Stock (NASDAQ:CORT)Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Read More CORT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CORT Stock News HeadlinesMarch 21, 2024 | insidertrades.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sean Maduck Sells 17,219 SharesMarch 22, 2024 | americanbankingnews.comSean Maduck Sells 17,219 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) StockMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 19, 2024 | americanbankingnews.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Given Average Rating of "Moderate Buy" by BrokeragesMarch 17, 2024 | finance.yahoo.comCORT May 2024 32.000 callMarch 17, 2024 | finance.yahoo.comCORT Apr 2024 31.000 callMarch 16, 2024 | finance.yahoo.comCORT Apr 2024 17.000 putMarch 16, 2024 | finance.yahoo.comCORT Aug 2024 32.000 putMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 11, 2024 | stocknews.comTop 3 Biotech Stocks to Anchor Your PortfolioFebruary 29, 2024 | money.usnews.comCorcept Therapeutics IncFebruary 28, 2024 | stocknews.comPlunge into Profits With These 3 Biotech StocksFebruary 25, 2024 | realmoney.thestreet.comA Checkdown Trade on a Small-Cap Biotech StockFebruary 24, 2024 | msn.comCorcept Therapeutics (CORT) Price Target Increased by 14.13% to 43.66February 19, 2024 | seekingalpha.comCorcept Therapeutics: Key Catalysts AheadFebruary 17, 2024 | finance.yahoo.comCorcept Therapeutics Full Year 2023 Earnings: Beats ExpectationsFebruary 17, 2024 | msn.comBad News for Corcept Therapeutics Stock: This New Risk Has Been AddedFebruary 16, 2024 | realmoney.thestreet.comCorcept Therapeutics price target raised by $6 at Truist, here's whyFebruary 16, 2024 | msn.comWhat's Going On With Stress Hormone Modulator-Focused Corcept Therapeutics' Stock Friday?February 16, 2024 | finance.yahoo.comCorcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales GrowFebruary 16, 2024 | markets.businessinsider.comCorcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical TrialFebruary 16, 2024 | finance.yahoo.comQ4 2023 Corcept Therapeutics Inc Earnings CallFebruary 16, 2024 | finance.yahoo.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Call TranscriptFebruary 16, 2024 | finanznachrichten.deCorcept Therapeutics Incorporated: Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical TrialFebruary 15, 2024 | benzinga.comRecap: Corcept Therapeutics Q4 EarningsFebruary 15, 2024 | finance.yahoo.comCorcept Therapeutics Inc Reports Significant Revenue Growth and Net Income Increase in Q4 and ...February 15, 2024 | globenewswire.comCorcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate UpdateSee More Headlines Receive CORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today3/28/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CORT CUSIP21835210 CIK1088856 Webwww.corcept.com Phone(650) 327-3270Fax650-327-3218Employees352Year Founded1998Price Target and Rating Average Stock Price Target$33.79 High Stock Price Target$47.50 Low Stock Price Target$25.00 Potential Upside/Downside+32.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.95 Trailing P/E Ratio26.78 Forward P/E Ratio27.65 P/E GrowthN/ANet Income$106.14 million Net Margins21.86% Pretax Margin25.82% Return on Equity21.98% Return on Assets17.89% Debt Debt-to-Equity RatioN/A Current Ratio4.39 Quick Ratio4.31 Sales & Book Value Annual Sales$482.38 million Price / Sales5.46 Cash Flow$0.98 per share Price / Cash Flow25.84 Book Value$4.92 per share Price / Book5.17Miscellaneous Outstanding Shares103,520,000Free Float83,021,000Market Cap$2.63 billion OptionableOptionable Beta0.47 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Joseph K. Belanoff M.D. (Age 67)Co-Founder, President, CEO & Director Comp: $1.82MMr. Atabak Mokari (Age 47)CFO & Treasurer Comp: $760.75kDr. Hazel Hunt Ph.D. (Age 64)Chief Scientific Officer Comp: $895.16kMr. Sean Maduck (Age 46)President of Endocrinology Comp: $823.42kMr. Gary Charles Robb (Age 61)Chief Business Officer & Secretary Comp: $963kMr. Joseph Douglas Lyon (Age 45)Chief Accounting Officer Ms. Amy FloodChief Human Resources & Communications OfficerDr. William Guyer Pharm.D. (Age 56)Chief Development Officer Ms. Monica Tellado (Age 51)President of Emerging Markets Mr. Roberto W. VieiraPresident of OncologyMore ExecutivesKey CompetitorsRa PharmaceuticalsNASDAQ:RARXSupernus PharmaceuticalsNASDAQ:SUPNTaro Pharmaceutical IndustriesNYSE:TAROAxsome TherapeuticsNASDAQ:AXSMPacira BioSciencesNASDAQ:PCRXView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 2,432 shares on 3/22/2024Ownership: 0.011%Sean MaduckSold 17,219 sharesTotal: $430,475.00 ($25.00/share)Vanguard Group Inc.Bought 239,887 shares on 3/11/2024Ownership: 9.213%Wellington Management Group LLPBought 40,385 shares on 3/5/2024Ownership: 0.039%Goldman Sachs Group Inc.Bought 124,185 shares on 3/1/2024Ownership: 0.515%View All Insider TransactionsView All Institutional Transactions CORT Stock Analysis - Frequently Asked Questions Should I buy or sell Corcept Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CORT shares. View CORT analyst ratings or view top-rated stocks. What is Corcept Therapeutics' stock price target for 2024? 6 Wall Street analysts have issued 1 year price objectives for Corcept Therapeutics' stock. Their CORT share price targets range from $25.00 to $47.50. On average, they anticipate the company's stock price to reach $33.79 in the next year. This suggests a possible upside of 32.5% from the stock's current price. View analysts price targets for CORT or view top-rated stocks among Wall Street analysts. How have CORT shares performed in 2024? Corcept Therapeutics' stock was trading at $32.48 at the start of the year. Since then, CORT stock has decreased by 21.5% and is now trading at $25.49. View the best growth stocks for 2024 here. When is Corcept Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our CORT earnings forecast. How were Corcept Therapeutics' earnings last quarter? Corcept Therapeutics Incorporated (NASDAQ:CORT) released its earnings results on Thursday, February, 15th. The biotechnology company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.03. The biotechnology company had revenue of $135.41 million for the quarter, compared to analysts' expectations of $129.27 million. Corcept Therapeutics had a trailing twelve-month return on equity of 21.98% and a net margin of 21.86%. The firm's quarterly revenue was up 31.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 EPS. What ETFs hold Corcept Therapeutics' stock? ETFs with the largest weight of Corcept Therapeutics (NASDAQ:CORT) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Hartford Multifactor Small Cap ETF (ROSC) and Distillate Small/Mid Cash Flow ETF (DSMC). What guidance has Corcept Therapeutics issued on next quarter's earnings? Corcept Therapeutics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $600.0 million-$630.0 million, compared to the consensus revenue estimate of $531.6 million. What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO? 6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Corcept Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI). Who are Corcept Therapeutics' major shareholders? Corcept Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.25%), Vanguard Group Inc. (9.21%), Ingalls & Snyder LLC (8.10%), Parallel Advisors LLC (3.66%), Novo Holdings A S (2.34%) and Dimensional Fund Advisors LP (2.24%). Insiders that own company stock include Daniel N Swisher Jr, Daniel N Swisher, Jr, David L Mahoney, G Leonard Baker, Jr, Gary Charles Robb, Hazel Hunt, Joseph Douglas Lyon, Joseph K Belanoff, Sean Maduck and William Guyer. View institutional ownership trends. How do I buy shares of Corcept Therapeutics? Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CORT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.